InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April...

InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference,
April 25

-- Conference Call and Webcast Scheduled --

BRISBANE, Calif., April 20 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq:
ITMN) today announced that InterMune and Pharmasset, Inc. will host a live
webcast of a discussion of the INFORM-1 results from the EASL conference on
Saturday, April 25, 2009, at 7:00 p.m. CEST (1:00 p.m. EDT). Participating in
the discussion will be Ed Gane, M.D., principal investigator in the INFORM-1
trial. Members of management from Roche, InterMune and Pharmasset will also
be available to answer questions.

Dial-In and Webcast Details
A live webcast and slide presentation will be available through the Investor
Relations pages of both InterMune and Pharmasset at www.intermune.com or
www.pharmasset.com, respectively. Alternatively, interested parties may
access the discussion and ask questions by dialing 888-799-0528 (U.S. &
Canada) or 973-200-3372 (International), conference ID # 95452531. A webcast
replay will be available approximately three hours after the call and will be
archived at www.intermune.com and at www.pharmasset.com.

The companies recommend logging on at least 15 minutes prior to the start of
the webcast to ensure adequate time for any software downloads that may be
required.

The teleconference replay will be available for 10 business days following the
call and can be accessed by dialing 800-642-1687 (U.S. & Canada) or
706-645-9291 (international), and entering conference ID # 95452531.

About InterMune
InterMune is a biotechnology company focused on the research, development and
commercialization of innovative therapies in pulmonology and hepatology.
InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF)
and hepatitis C virus (HCV) infections. The pulmonology portfolio includes
pirfenidone for which a Phase 3 program in patients with IPF (CAPACITY) has
been completed and the compound is currently in the pre-registration stage.
The company also has a research program focused on a pirfenidone analog named
ITMN-520. The hepatology portfolio includes the HCV protease inhibitor
compound ITMN-191 (referred to as R7227 at Roche) expected to enter Phase 2b
in the summer of 2009 and a second-generation HCV protease inhibitor research
program. For additional information about InterMune and its R&D pipeline,
please visit www.intermune.com.

SOURCE InterMune, Inc.

Jim Goff of InterMune, Inc., +1-415-466-2228, jgoff@intermune.com